Reported Consolidated quarterly numbers for Strides Pharma Science are:Net Sales at Rs 688.37 crore in June 2021 down 11.95% from Rs. 781.80 crore in June 2020.
Quarterly Net Loss at Rs. 205.20 crore in June 2021 down 298.14% from Rs. 103.56 crore in June 2020.
EBITDA stands negative at Rs. 36.71 crore in June 2021 down 121.95% from Rs. 167.21 crore in June 2020.
Strides Pharma shares closed at 681.20 on August 09, 2021 (NSE) and has given -19.85% returns over the last 6 months and 11.85% over the last 12 months.
| Strides Pharma Science | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'21 | Mar'21 | Jun'20 | | Net Sales/Income from operations | 688.37 | 908.49 | 781.80 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 688.37 | 908.49 | 781.80 | | EXPENDITURE | | Consumption of Raw Materials | 316.93 | 402.77 | 276.69 | | Purchase of Traded Goods | 60.78 | 115.76 | 44.04 | | Increase/Decrease in Stocks | -28.63 | -147.01 | -18.48 | | Power & Fuel | -- | -- | -- | | Employees Cost | 161.36 | 153.70 | 129.78 | | Depreciation | 54.88 | 51.86 | 49.13 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 228.17 | 226.04 | 194.86 | | P/L Before Other Inc., Int., Excpt. Items & Tax | -105.12 | 105.38 | 105.77 | | Other Income | 13.53 | 13.05 | 12.31 | | P/L Before Int., Excpt. Items & Tax | -91.59 | 118.43 | 118.08 | | Interest | 41.45 | 41.61 | 36.91 | | P/L Before Exceptional Items & Tax | -133.04 | 76.82 | 81.17 | | Exceptional Items | -91.54 | -0.93 | 44.92 | | P/L Before Tax | -224.58 | 75.89 | 126.09 | | Tax | -35.54 | 11.49 | 3.28 | | P/L After Tax from Ordinary Activities | -189.04 | 64.40 | 122.80 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -0.83 | -- | | Net Profit/(Loss) For the Period | -189.04 | 63.57 | 122.80 | | Minority Interest | 3.37 | 2.34 | 1.72 | | Share Of P/L Of Associates | -19.53 | -19.82 | -20.96 | | Net P/L After M.I & Associates | -205.20 | 46.09 | 103.56 | | Equity Share Capital | 89.72 | 89.68 | 89.55 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -22.88 | 5.14 | 11.56 | | Diluted EPS | -22.88 | 5.14 | 11.56 | | EPS After Extra Ordinary | | Basic EPS | -22.88 | 5.14 | 11.56 | | Diluted EPS | -22.88 | 5.14 | 11.56 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|